Skip to main content

Table 2 Baseline serum cytokines in Cohort 1 (hepatic arterial infusion chemotherapy-treated patients)

From: Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

Cytokines (pg/mL, mean ± SE)

CR/PR group

SD/PD group

P-valuea

EGF

20.8 ± 3.8

21.6 ± 3.0

0.882

FGF

2.84 ± 1.63

8.40 ± 2.53

0.134

HGF

523.9 ± 50.3

739.8 ± 71.6

0.043

IFN-γ

0.109 ± 0.064

1.343 ± 0.699

0.203

IL-10

0.813 ± 0.169

1.239 ± 0.219

0.193

IL-12 (p70)

8.41 ± 1.17

10.77 ± 1.05

0.164

IL-2

0.297 ± 0.092

1.118 ± 0.568

0.299

IL-4

0.586 ± 0.170

1.213 ± 0.197

0.038

IL-5

17.3 ± 5.5

15.6 ± 2.0

0.718

IL-6

10.90 ± 3.94

9.05 ± 1.65

0.614

IL-8/CXCL8

61.3 ± 37.1

18.7 ± 2.7

0.119

CXCL10

358.3 ± 41.1

359.1 ± 30.3

0.988

CXCL9

176.6 ± 14.0

205.8 ± 30.6

0.502

PDGF-BB

152.5 ± 20.9

193.6 ± 24.3

0.265

SCF

14.1 ± 1.3

16.4 ± 1.0

0.189

SDF-1

60.3 ± 26.3

13.1 ± 5.0

0.022

TGF-β

5.17 ± 3.42

1.64 ± 0.71

0.188

TGF-α

34.0 ± 23.8

14.2 ± 6.3

0.307

TNF-α

1.23 ± 0.31

1.87 ± 0.30

0.184

VEGF-A

65.1 ± 9.4

83.6 ± 6.9

0.116

  1. CR complete response, PD progressive disease, PR partial response, SD stable disease, SE standard error
  2. aUnpaired t-tests